NCT03093909View on ClinicalTrials.gov

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 22, 2017

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Malignant Neoplasm of Bone and Articular CartilageMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Independent (Primary) Multiple SitesMalignant Neoplasms of Lip Oral Cavity and PharynxMalignant Neoplasm of Male Genital OrgansMalignant Neoplasms of Mesothelial and Soft TissueMalignant Neoplasm of Respiratory and Intrathoracic Organ CarcinomaMalignant Neoplasms of Thyroid and Other Endocrine GlandsMalignant Neoplasms of Urinary TractMelanoma and Other Malignant Neoplasms of Skin
Interventions
DRUG

Gemcitabine

Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.

Trial Locations (1)

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

James B. and Lois R. Archer Charitable Foundation

UNKNOWN

collaborator

Gateway for Cancer Research

OTHER

lead

M.D. Anderson Cancer Center

OTHER